Century Therapeutics, Inc. Return Tang Equity
Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
- Century Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was -48.23%, a change of -36.89% year-over-year.
- Century Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was -41.45%, a change of -32.14% year-over-year.
- Century Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was -6.21%, a change of 74.60% year-over-year.
- Century Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was -15.43%, a change of 52.59% year-over-year.
- Century Therapeutics, Inc. return tang equity for fiscal 2025 was -6.03%, a change of 72.41% from fiscal 2024.
- Century Therapeutics, Inc. return tang equity for fiscal 2024 was -78.44%, a change of -4.46% from fiscal 2023.
- Century Therapeutics, Inc. return tang equity for fiscal 2023 was -73.98%, a change of -30.73% from fiscal 2022.
- Century Therapeutics, Inc. return tang equity for fiscal 2022 was -43.25%, a change of -19.07% from fiscal 2021.
- Available history
- 2020-12-31 to 2026-06-30
- Data captured
Historical Return Tang Equity
Annual Return Tang Equity
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |